Six years into NATALEE, the key question is no longer whether adjuvant ribociclib improves iDFS. Does the benefit remain durable-and is an OS signal emerging? LBA25 at #ESMO26, led by Dennis J. Slamon, with investigators @KalinskyKevin @LoiSher. What would change your practice most: absolute iDFS gain, OS maturity, or long-term treatment burden? #bcsm